EP PerMed Joint Transnational Call (JTC) 2025:
“Pharmacogenomic Strategies for Personalised Medicine Approaches (PGxPM2025)”
The European Partnership for Personalised Medicine, EP PerMed, supported by the European Union under Horizon Europe, Grant Agreement N° 101137129, has launched its second joint transnational call (JTC2025) for proposals on “Pharmacogenomic strategies for personalised medicine approaches (PGxPM2025)”. In total, 35 funding organisations participate in this call with an available budget of over 36.5 Mio. € (approx.).
EP PerMed funding organisations have agreed to jointly fund multinational innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe in this field.
The call will be implemented in two stages, i.e. a pre- and a full-proposal phase.
Electronic proposal submission is mandatory on PT-Outline. Research project consortia who intend to submit a transnational proposal should register as soon as possible: https://ptoutline.eu/app/EPPERMED2025
Deadline Pre-Proposal submission: 18 February, 2025: 14:00 h
Call Information Day – 09 January 2025: 12:45 – 14:30 h
Deadline Full-Proposal submission: 17 June, 2025: 14:00 h
The overall objectives of the JTC2025 will be to
Support research projects in human health on pharmacogenomic strategies for personalised medicine approaches that address one or more of the following aspects:
identification of new pharmacogenomic markers or signatures using (multi)-omics data in relation to drug or drug combination.
validation of a pharmacogenomic marker or signatures using (multi)-omics data in predicting drug or drug combination outcomes.
use pharmaco-omics strategies to determine the right dosage, the efficacy of treatments and/or the risk of adverse drug response and non-response to treatment to tailor personalised treatment pathways, including combined treatments (multi-medication).
Encourage and enable interdisciplinary collaborations,
Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations.
Establish participatory research, i.e. active representation of patients or citizens as part of research projects.
Projects are encouraged to combine the following aspects in their research:
Omics data such as epigenomics, transcriptomics, proteomics and metabolomics data in addition to genomics data in relation to treatment outcomes. A key goal is to assess the importance of one or more -omics approaches (multi-modal approaches) in optimising treatment outcomes.
Information regarding patient medication (prescription and non-prescription), dose or compliance.
Information (including clinical and environmental factors) regarding medication efficacy, adverse effects and patient reported outcomes (PRO).
